Until now, the Pfizer laboratory had only obtained an emergency temporary authorization in the United States to deliver its vaccines. This authorization runs until December 11, 2020. Finally, the US Medicines Agency, the FDA, should fully approve Pfizer and BioNtech’s vaccine against Covid-19 in September, says the New York Times mardi.
According to the newspaper which quotes sources familiar with the matter, “the unofficial date” on which the anti-Covid vaccine should get the full green light from the FDA “is around Labor Day (September 6, Editor’s note) or sooner “.
Last week, the FDA said in a statement that the approval process for the anti-Covid vaccine was “among the agency’s highest priorities” and that it expected to render its decision well before the end of the deadline.
Increase the confidence of Americans
Full serum approval could increase confidence and push more Americans to get vaccinated at a time when the highly contagious Delta variant of Covid is spiking the number of cases in the country.
About 192 million Americans have received at least one dose of vaccine (Pfizer, Moderna or Johnson and Johnson), or 58% of the population or 70% of adults.
At the same time, as of July 27, according to figures from the Centers for Disease Prevention and Control (CDC), Covid-19 cases have risen to 66,000 per day, six times more than in June.
Moderna, the other widely used vaccine, also authorized under an emergency regime, also applied, but later, applied for full approval. Johnson and Johnson and his one-dose vaccine has yet to request it, according to the newspaper.